Biotech RadarJobs updated

COMPANY

Erasca

HQ: San Diego, CA source · erasca.com ↗ · West Coast

Clinical Phase 3

6 open jobs · last seen Oct 23, 2026 · 11 sources

Erasca is a clinical-stage precision oncology company discovering, developing and commercializing therapies for RAS- and MAPK pathway-driven cancers. From company website Source · Oct 12, 2026

Keywords: oncology Metastatic Colorectal Cancer Metastatic Pancreatic Ductal Adenocarcinoma Advanced or Metastatic NRAS-mutant Melanoma Advanced Non-squamous Non-small-cell Lung Cancer Acute Myeloid Leukemia ERAS-601 ERAS-007 ERAS-0015 ERAS-4001

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

6Open jobs$808.8MRaised (2 yrs)9Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Exec Director/VP Regulatory AffairsSan Diego, South San Francisco, or remoteOct 21, 2026Oct 22, 2026
Sr Manager/Assoc Director, Regulatory OperationsSan Diego, South San Francisco, or remoteOct 21, 2026Oct 22, 2026
SVP Clinical Development & Global Program Lead, Pancreatic CancerSan Diego, CA; South San Francisco, CA; remoteSep 24, 2026Oct 16, 2026
Clinical Trial Manager/Sr Clinical Trial ManagerSan Diego, CA or remoteJun 11, 2026Oct 19, 2026
Senior Manager, Pharmaceutical DevelopmentSouth San Francisco, CAJun 10, 2026Oct 16, 2026

See all 6 jobs

Timeline

  1. Raise Follow-on offering: $550M (total, as published), announced Jul 13, 2026. Source: SEC filing. source ↗
  2. Raise Follow-on offering: $258.8M (total, as published), announced Jan 23, 2026. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 1: A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. source ↗
  4. Trial start Phase 1: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors source ↗
  5. Trial start Phase 3: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) source ↗
  6. Trial start Phase 1: A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations source ↗
  7. Trial start Phase 1/Phase 2: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies source ↗
  8. Trial start Phase 1/Phase 2: A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies source ↗
  9. Trial start Phase 1: A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC source ↗
  10. Trial start Phase 1/Phase 2: A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors source ↗
  11. Trial start Phase 1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $808.8M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT04670679A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid TumorsPhase 1CompletedDec 15, 2020Feb 1, 2026 (actual)
NCT04866134A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid TumorsPhase 1/Phase 2CompletedMay 7, 2021Jul 1, 2026 (actual)
NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsPhase 1RecruitingJun 5, 2025May 1, 2028 (estimated)
NCT05039177A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesPhase 1/Phase 2CompletedSep 20, 2021Aug 15, 2025 (actual)
NCT05907304A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X MutationsPhase 1Active, not recruitingAug 17, 2023Jul 1, 2025 (actual)
NCT06346067A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Phase 3Active, not recruitingApr 29, 20242028-04 (estimated)
NCT07021898A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.Phase 1RecruitingAug 6, 20252028-08 (estimated)
NCT04959981A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCPhase 1CompletedSep 2, 2021Apr 27, 2023 (actual)
NCT05279859A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesPhase 1/Phase 2WithdrawnMar 15, 2022Mar 1, 2025 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Open jobs 6

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Exec Director/VP Regulatory AffairsSan Diego, South San Francisco, or remoteOct 21, 2026Oct 22, 2026Not stated
Sr Manager/Assoc Director, Regulatory OperationsSan Diego, South San Francisco, or remoteOct 21, 2026Oct 22, 2026Not stated
SVP Clinical Development & Global Program Lead, Pancreatic CancerSan Diego, CA; South San Francisco, CA; remoteSep 24, 2026Oct 16, 2026Not stated
Clinical Trial Manager/Sr Clinical Trial ManagerSan Diego, CA or remoteJun 11, 2026Oct 19, 2026Not stated
Senior Manager, Pharmaceutical DevelopmentSouth San Francisco, CAJun 10, 2026Oct 16, 2026Not stated
SVP BiometricsSan Diego, CA, South San Francisco, CA, or remoteMay 14, 2026Oct 16, 2026Not stated

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at Erasca on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback